Merck

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Merck and other ETFs, options, and stocks.

About MRK

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. 

CEO
Robert M. Davis
CEORobert M. Davis
Employees
72,000
Employees72,000
Headquarters
Rahway, New Jersey
HeadquartersRahway, New Jersey
Founded
1891
Founded1891
Employees
72,000
Employees72,000

MRK Key Statistics

Market cap
246.46B
Market cap246.46B
Price-Earnings ratio
20.22
Price-Earnings ratio20.22
Dividend yield
3.19%
Dividend yield3.19%
Average volume
11.37M
Average volume11.37M
High today
$98.84
High today$98.84
Low today
$96.60
Low today$96.60
Open price
$96.80
Open price$96.80
Volume
12.14M
Volume12.14M
52 Week high
$134.63
52 Week high$134.63
52 Week low
$94.48
52 Week low$94.48

MRK News

TipRanks 13h
Pyxis Oncology announces preliminary PYX-201 data, collaboration with Merck

Pyxis Oncology (PYXS) announced preliminary data from the ongoing Phase 1 clinical dose escalation study evaluating PYX-201 in multiple types of solid tumors. P...

TipRanks 20h
Johnson & Johnson, Merck cutting jobs in China, Bloomberg reports

Johnson & Johnson (JNJ) and Merck (MRK) are cutting jobs in China as they face growing competition from domestic rivals resulting from Beijing’s campaign to dri...

TipRanks 21h
Merck target upped at Jefferies after ‘important win’ with subcutaneous Keytruda

Jefferies raised the firm’s price target on Merck (MRK) to $149 from $148 and keeps a Buy rating on the shares after subcutaneous administration of pembrolizuma...

Analyst ratings

78%

of 27 ratings
Buy
77.8%
Hold
22.2%
Sell
0%

More MRK News

Seeking Alpha 2d
Merck readies new Keytruda version ahead of major regulatory headwinds

Merck (NYSE:MRK) marked a major milestone in its bid to introduce a new formulation for its famous cancer therapy pembrolizumab on Tuesday as its blockbuster in...

Merck readies new Keytruda version ahead of major regulatory headwinds
TipRanks 2d
Merck ‘linked’ to takeover bid for Incyte, Sky News says

Mark Kleinman, Sky News’ City editor, posted on X, the service formerly known as Twitter: “Revealed: Merck (MRK), the US-listed pharma group, is the latest indu...

Benzinga 2d
Merck's Multi-Billion Dollar Drug Keytruda's Investigational Under The Skin Injection At Par With Intravenous Formulation In Untreated Lung Cancer Patients

On Tuesday, Merck & Co Inc MRK revealed topline results from the pivotal Phase 3 MK-3475A-D77 trial evaluating the noninferiority of subcutaneous administration...

Merck's Multi-Billion Dollar Drug Keytruda's Investigational Under The Skin Injection At Par With Intravenous Formulation In Untreated Lung Cancer Patients
Simply Wall St 6d
The Strong Earnings Posted By Merck Are A Good Indication Of The Strength Of The Business

The subdued stock price reaction suggests that Merck & Co., Inc.'s ( ) strong earnings didn't offer any surprises. Investors are probably missing some underlyin...

The Strong Earnings Posted By Merck Are A Good Indication Of The Strength Of The Business
TipRanks 6d
Wolfe starts Merck at Peer Perform, notes competitive overhangs

Wolfe Research initiated coverage of Merck (MRK) with a Peer Perform rating. The firm said the main sentiment driver for Merck is Gardasil’s outlook in China, a...

Seeking Alpha 7d
Merck to buy rights to Chinese cancer drug for up to $3.3B

Merck (NYSE:MRK) and LaNova Medicines announced Thursday an agreement under which the U.S. pharmaceutical giant is expected to obtain licensing rights to a canc...

Merck to buy rights to Chinese cancer drug for up to $3.3B
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.